Navigation Links
The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients

rable" responses with improved tolerability, even in patients who had stopped responding to either drug when used alone. The data presented this week showed a 100 percent response rate in newly diagnosed patients and a 68 percent response rate in relapsed patients.

"The number of options available to treat myeloma patients today is growing with positive results from mature studies, as well as preliminary results from smaller trials," said Brian G.M. Durie, M.D. chairman and co- founder of the IMF. "What we are learning from using these novel combinations in myeloma is so promising that our findings may become applicable to many malignancies including lung, ovarian and other cancers. The progress we've begun in myeloma is encouraging for all cancer patients around the world."

Myeloma, also called multiple myeloma, is a cancer of cells in the bone marrow that affects production of red cells, white cells and stem cells. It affects an estimated 750,000 people worldwide, and in industrialized countries it is being diagnosed in growing numbers and in increasingly younger people.

ABOUT THE INTERNATIONAL MYELOMA FOUNDATION

The International Myeloma Foundation is the oldest and largest myeloma organization, reaching more than 135,000 members in 113 countries worldwide. A 501 (c) 3 non-profit organization dedicated to improving the quality of life of myeloma patients and their families, the IMF focuses in four key areas: research, education, support and advocacy. To date, the IMF has conducted more than 120 educational seminars worldwide, maintains a world-renowned hotline, and operates Bank On A Cure(R), a unique gene bank to advance myeloma research. The IMF can be reached at (800) 452-CURE or http://www.myeloma.org, and in Spanish at http://www.myelomala.org.

Contact: Stephen Gendel

              The International Myel
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
(Date:8/21/2014)... 2014   Royal Philips (NYSE: ... has received 510(k) clearance from the U.S. Food ... application for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through ... with pre-procedural, high-precision positioning to treat aortic stenosis ... is available as part of Philips IntelliSpace ...
(Date:8/21/2014)... 21, 2014  SI-BONE, Inc. ( San Jose, ... the use of the iFuse Implant System, ® ... of the sacroiliac (SI) joint, announced that Priority Health ... its Lumbar Fusion Medical Policy No. 91590-R4 providing positive ... policy states that the fusion procedure, which employs the ...
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium Pharmaceuticals, ... specialty biopharmaceutical company, today announced positive results from ... clostridium histolyticum (or CCH) for the treatment of ... In the Phase 2a trial, all three doses ... (0.84mg)) showed an improvement in the appearance of ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7
(Date:8/22/2014)... News) -- The air in American cities is getting ... Thursday. Significant progress has been made in reducing ... decades, the agency said in a news release. ... reduction in mercury from human sources such as coal-fired ... 84 percent fall in lead, which harms brain development ...
(Date:8/22/2014)... leather seat covers provided by Lseat.comare meticulously in house ... needs. Recently, the company has unveiled its latest assortment of ... wants to provide worldwide clients with more high quality items. ... a long time. According to the company’s sales manager, all ... all the new products, Chevrolet Camaro leather seat covers ...
(Date:8/22/2014)... NY (PRWEB) August 22, 2014 ... Chinese orthopedic instrument industry, some foreign and domestic ... instrument market though mergers and acquisitions. In 2012, ... maker in China-- China Kanghui Holdings for USD ... China’s largest trauma product makers-- Trauson Holdings Company ...
(Date:8/22/2014)... The graft-versus-host disease (GVHD) treatment market value will ... by 2018, at a Compound Annual Growth Rate (CAGR) ... – Opportunity Analysis and Forecasts to 2018” states that ... (6MM: the US, France, Germany, Italy, Spain and the ... (5EU), where multiple product launches will accelerate the market ...
(Date:8/22/2014)... 2014 Tug McGraw Foundation and Team McGraw ... to participate in the 39th Annual Marine Corps Marathon on ... will join forces in coaching, training and participation for the ... our nation's capital and is often referred to as the ... Corps Marathon is the largest marathon in the world that ...
Breaking Medicine News(10 mins):Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2Health News:Custom 1993-1996 Chevrolet Camaro Leather Seat Covers Now for Sale at Lseat.com 2Health News:China Orthopedic Instrument Industry 2014- Global Industry Size, Share, Trend, Growth and Forecast 2017 2Health News:Graft-Versus-Host Disease Treatment Market Worth $409.0m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Graft-Versus-Host Disease Treatment Market Worth $409.0m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Graft-Versus-Host Disease Treatment Market Worth $409.0m by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Tug McGraw Foundation and Team Red White and Blue Join to Run in Marine Corps Marathon 2Health News:Tug McGraw Foundation and Team Red White and Blue Join to Run in Marine Corps Marathon 3
... Offered to Cancer Patients in HELIOS HospitalsBERLIN, March 10 ... Germany will gain access to the most modern radiotherapy ... that it is acquiring nine linear accelerators from Varian ... of them equipped with RapidArc(TM) technology for fast and ...
... are embracing technological advances, such as electronic medical records, ... their needs.Those are the results found in a recent ... The findings were published in the March/April issue of ... conducted the same survey back in 2004. Five years ...
... Inc. (TSX: DDS; NASDAQ: DDSS ) today announced ... will present at the Cowen and Company 29th Annual Health ... March 18, 2009 at 11:00 a.m. ET. , Interested parties ... the "Events" section of the homepage of the Company,s website ...
... Pressure Profile Systems, Inc. Combines Tactile and 3D ... Footbeds to ConsumersLOS ANGELES and SCOTTSDALE, Ariz., March ... (PPS) together with its partner eSoles, LLC, today ... (R) Kiosk Scanning System. The free-standing, ...
... KONG, March 10 /PRNewswire-Asia/ -- Obio Pharmaceutical Holdings Ltd,("Obio"/ ... of a drug,TG21, against main strains of influenza virus ... H5N1. The process leading to clinical,trials for TG21 has ... and will continue to engage prestigious institutions in USA ...
... Awareness of the KeepingYouWell.com Website for People Seeking Quality Care ... ... Blue Search Engine Marketing is pleased to announce Adventist Midwest Health ... on for a unique, highly targeted search engine optimization campaign, and ...
Cached Medicine News:Health News:Leading German Healthcare Group Selects Equipment and Software from Varian Medical Systems for Major Replacement Project 2Health News:Survey Results: Health Care Technology Advances as Physician Frustration Grows 2Health News:World's Most Advanced Foot Scanning Kiosk Made Available to Retailers by eSoles and Pressure Profile Systems, Inc. 2Health News:Obio Pharmaceutical Announced New Antiviral Drug Discovery to Combat Influenza Virus 2Health News:Obio Pharmaceutical Announced New Antiviral Drug Discovery to Combat Influenza Virus 3Health News:Adventist Midwest Health Engages Medium Blue Search Engine Marketing in Geographically-Targeted SEO Campaign 2Health News:Adventist Midwest Health Engages Medium Blue Search Engine Marketing in Geographically-Targeted SEO Campaign 3
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
Inquire...
Medicine Products: